Dr. Lewis disclosed that he consults for AbbVie, Janssen, Prometheus, and Millennium and has received research funding from Centocor and Takeda.
News
Trial immunosuppressive therapy benefits outweigh long-term lymphoma risks in IBD
Publish date: January 22, 2014
EXPERT ANALYSIS AT 2013 ADVANCES IN IBD